查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477111

非病毒藥物傳輸系統市場，按分子、生物製劑、治療領域、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Non-Viral Drug Delivery Systems Market, By Molecules, By Biologics, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023 年非病毒藥物輸送系統市場規模為 71.23 億美元，2024 年至 2032 年複合年成長率為 12.5%。

非病毒藥物傳輸系統市場-市場動態

癌症盛行率上升推動市場需求

全球癌症盛行率的不斷上升預計將在預測期內推動市場成長。例如，根據世界衛生組織預測，到 2022 年，預計將有 2,000 萬新發癌症病例和 970 萬人死於該疾病。五分之一的人會在一生中的某個階段罹患癌症；九分之一的男性和十二分之一的女性將死於這種疾病。

非病毒藥物傳輸系統市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 12.5% 左右的複合年成長率成長

根據分子，小分子細分市場預計在預測期內將以最高複合年成長率成長

根據治療領域細分，腫瘤疾病領域預計將在預測期內引領市場

按地區分類，北美是 2023 年的主要收入來源

非病毒藥物傳輸系統市場區隔分析：

全球非病毒藥物傳輸系統市場根據分子、生物製劑、治療領域和地區進行細分。

根據分子，市場分為小分子和大分子。預計小分子細分市場在預測期內將以最高複合年成長率成長。隨著科學家和製藥公司尋找創新方法來改善小分子藥物治療一系列疾病的輸送和有效性，小分子非病毒藥物輸送系統的市場預計將繼續成長。

依治療領域，該產業分為傳染病、腫瘤疾病、遺傳疾病、神經系統疾病、肝臟疾病、心血管疾病等。預計腫瘤疾病領域將在預測期內引領市場。該細分市場的擴張歸因於癌症盛行率的上升。

非病毒藥物傳輸系統市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內主導市場。區域市場的擴張歸因於慢性病的高盛行率。此外，研發支出的高額也是推動該地區市場成長的重要因素。

非病毒藥物輸送系統市場-競爭格局：

市場的主要參與者包括 Arcturus Therapeutics、Bio-Path Holdings、CureVac、Entos Pharmaceuticals、eTheRNA、Matinas BioPharma、MDimune 和 PCI Biotech。這些參與者採取了多種策略來獲取最大的市場佔有率，例如產品發布、收購、擴張等。

目錄

第 1 章：非病毒藥物傳輸系統市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 非病毒藥物傳輸系統市場分子片段
    • 生物製品的非病毒藥物傳輸系統市場片段
    • 按治療領域分類的非病毒藥物傳輸系統市場片段
    • 按國家/地區分類的非病毒藥物傳輸系統市場片段
    • 按地區分類的非病毒藥物傳輸系統市場片段
  • 競爭洞察

第 3 章：非病毒藥物傳輸系統主要市場趨勢

  • 非病毒藥物傳輸系統市場促進因素
    • 市場促進因素的影響分析
  • 非病毒藥物傳輸系統市場限制
    • 市場限制影響分析
  • 非病毒藥物傳輸系統市場機會
  • 非病毒藥物傳輸系統市場未來趨勢

第 4 章：非病毒藥物輸送系統產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：非病毒藥物傳輸系統市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：非病毒藥物傳輸系統市場格局

  • 2023 年非病毒給藥系統市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：非病毒藥物輸送系統市場 - 按分子

  • 概述
    • 按分子分類的細分市場佔有率分析
    • 小分子
    • 大分子

第 8 章：非病毒藥物傳輸系統市場 - 依生物製劑

  • 概述
    • 按生物製品分類的細分市場佔有率分析
    • RNAi/mRNA
    • DNA寡核苷酸
    • 抗體
    • 蛋白質/胜肽

第 9 章：非病毒藥物傳輸系統市場 - 按治療領域

  • 概述
    • 按治療領域分類的細分市場佔有率分析
    • 傳染性疾病
    • 腫瘤疾病
    • 遺傳性疾病
    • 神經系統疾病
    • 肝臟疾病
    • 心血管疾病
    • 其他

第 10 章：非病毒藥物傳輸系統市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美非病毒藥物傳輸系統主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按分子）
    • 北美生物製劑市場規模與預測
    • 北美市場規模與預測（按治療領域）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲非病毒藥物傳輸系統主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按分子）
    • 歐洲生物製劑市場規模與預測
    • 歐洲市場規模與預測（按治療領域）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區非病毒藥物傳輸系統主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 按分子分類的亞太市場規模和預測
    • 亞太地區生物製劑市場規模與預測
    • 按治療領域分類的亞太市場規模和預測
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲非病毒藥物傳輸系統主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按分子）
    • 拉丁美洲生物製劑市場規模與預測
    • 拉丁美洲市場規模與預測（按治療領域）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲非病毒藥物傳輸系統主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按分子）
    • 中東及非洲生物製品市場規模及預測
    • 中東和非洲市場規模及預測（按治療領域）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 非病毒藥物輸送系統產業

  • 競爭儀表板
  • 公司簡介
    • Arcturus Therapeutics
    • Bio-Path Holdings
    • CureVac
    • Entos Pharmaceuticals
    • eTheRNA
    • Matinas BioPharma
    • MDimune
    • PCI Biotech

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究治療領域學
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2507

REPORT HIGHLIGHT

Non-Viral Drug Delivery Systems Market size was valued at USD 7,123 Million in 2023, expanding at a CAGR of 12.5% from 2024 to 2032.

Systems for delivering therapeutic agents-such as medications, DNA, or proteins-into the body without the use of viral vectors are referred to as non-viral drug delivery systems. Non-viral delivery systems use a variety of artificial or natural carriers to deliver therapeutic payloads, in contrast to viral vectors that use viruses to insert genetic information into cells. These carriers can target particular cells or tissues, improve stability, shield the payload from deterioration, and make it easier for it to be released at the intended location of action.

Non-Viral Drug Delivery Systems Market- Market Dynamics

Increasing prevalence of cancer to propel market demand

The increasing prevalence of cancer across the globe is expected to drive market growth during the forecast period. For instance, according to the World Health Organization, 20 million new instances of cancer and 9.7 million deaths from the disease are predicted for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the illness.

Non-Viral Drug Delivery Systems Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2024-2032)

Based on molecule, the small molecules segment is expected to grow at the highest CAGR during the forecast period

Based on therapeutic area segmentation, the Oncological Disorders segment is expected to lead the market over the projected period

Based on region, North America was the leading revenue generator in 2023

Non-Viral Drug Delivery Systems Market- Segmentation Analysis:

The Global Non-Viral Drug Delivery Systems Market is segmented based on Molecules, Biologics, Therapeutic Area, and Region.

Based on the molecules, the market is categorized into Small Molecules and Large Molecules. The Small Molecules segment is expected to grow at the highest CAGR during the forecast period. As scientists and pharmaceutical firms look for innovative ways to improve the delivery and effectiveness of small molecule medications for a range of illnesses and ailments, the market for non-viral drug delivery systems for small molecules is expected to continue growing.

Based on the therapeutic area, the industry is divided into Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Others. The Oncological Disorders segment is expected to lead the market over the projected period. The segment expansion is attributed to the rising prevalence of cancer.

Non-Viral Drug Delivery Systems Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period. The regional market expansion is attributed to the high prevalence of chronic disease. Moreover, the high spending on R&D is also an important factor propelling the market growth in the region.

Non-Viral Drug Delivery Systems Market- Competitive Landscape:

The key players operating in the market include Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA, Matinas BioPharma, MDimune and PCI Biotech. These players adopted several strategies to capture the maximum market share such as product launch, acquisition, expansion and others.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Arcturus Therapeutics

Bio-Path Holdings

CureVac

Entos Pharmaceuticals

eTheRNA

Matinas BioPharma

MDimune

PCI Biotech

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY MOLECULES- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Large Molecules

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY BIOLOGICS- MARKET ANALYSIS, 2019 - 2032

  • RNAi / mRNA
  • DNA Oligonucleotides
  • Antibodies
  • Proteins / Peptides

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Oncological Disorders
  • Genetic Disorders
  • Neurological Disorders
  • Hepatic Disorders
  • Cardiovascular Disorders
  • Others

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Non-Viral Drug Delivery Systems Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Non-Viral Drug Delivery Systems Market Snippet by Molecules
    • 2.1.2.Non-Viral Drug Delivery Systems Market Snippet by Biologics
    • 2.1.3.Non-Viral Drug Delivery Systems Market Snippet by Therapeutic Area
    • 2.1.4.Non-Viral Drug Delivery Systems Market Snippet by Country
    • 2.1.5.Non-Viral Drug Delivery Systems Market Snippet by Region
  • 2.2.Competitive Insights

3.Non-Viral Drug Delivery Systems Key Market Trends

  • 3.1.Non-Viral Drug Delivery Systems Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Non-Viral Drug Delivery Systems Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Non-Viral Drug Delivery Systems Market Opportunities
  • 3.4.Non-Viral Drug Delivery Systems Market Future Trends

4.Non-Viral Drug Delivery Systems Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Non-Viral Drug Delivery Systems Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Non-Viral Drug Delivery Systems Market Landscape

  • 6.1.Non-Viral Drug Delivery Systems Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Non-Viral Drug Delivery Systems Market - By Molecules

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Molecules, 2023 & 2032 (%)
    • 7.1.2.Small Molecules
    • 7.1.3.Large Molecules

8.Non-Viral Drug Delivery Systems Market - By Biologics

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Biologics, 2023 & 2032 (%)
    • 8.1.2.RNAi / mRNA
    • 8.1.3.DNA Oligonucleotides
    • 8.1.4.Antibodies
    • 8.1.5.Proteins / Peptides

9.Non-Viral Drug Delivery Systems Market - By Therapeutic Area

  • 9.1.Overview
    • 9.1.1.Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 9.1.2.Infectious Diseases
    • 9.1.3.Oncological Disorders
    • 9.1.4.Genetic Disorders
    • 9.1.5.Neurological Disorders
    • 9.1.6.Hepatic Disorders
    • 9.1.7.Cardiovascular Disorders
    • 9.1.8.Others

10.Non-Viral Drug Delivery Systems Market- By Geography

  • 10.1.Introduction
    • 10.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2.North America
    • 10.2.1.Overview
    • 10.2.2.Non-Viral Drug Delivery Systems Key Manufacturers in North America
    • 10.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4.North America Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.2.5.North America Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.2.6.North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.2.7.U.S.
      • 10.2.7.1.Overview
      • 10.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3.U.S. Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.2.7.4.U.S. Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.2.7.5.U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.2.8.Canada
      • 10.2.8.1.Overview
      • 10.2.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3.Canada Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.2.8.4.Canada Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.2.8.5.Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.3.Europe
    • 10.3.1.Overview
    • 10.3.2.Non-Viral Drug Delivery Systems Key Manufacturers in Europe
    • 10.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4.Europe Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.3.5.Europe Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.3.6.Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.7.Germany
      • 10.3.7.1.Overview
      • 10.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3.Germany Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.7.4.Germany Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.7.5.Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.8.Italy
      • 10.3.8.1.Overview
      • 10.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3.Italy Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.8.4.Italy Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.8.5.Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.9.United Kingdom
      • 10.3.9.1.Overview
      • 10.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3.United Kingdom Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.9.4.United Kingdom Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.9.5.United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.10.France
      • 10.3.10.1.Overview
      • 10.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3.France Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.10.4.France Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.10.5.France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.11.Russia
      • 10.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2.Russia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.11.3.Russia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.11.4.Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.12.Netherlands
      • 10.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2.Netherlands Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.12.3.Netherlands Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.12.4.Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.13.Sweden
      • 10.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2.Sweden Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.13.3.Sweden Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.13.4.Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.14.Poland
      • 10.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2.Poland Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.14.3.Poland Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.14.4.Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.15.Rest of Europe
      • 10.3.15.1.Overview
      • 10.3.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3.Rest of the Europe Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.15.4.Rest of the Europe Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.15.5.Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.4.Asia Pacific (APAC)
    • 10.4.1.Overview
    • 10.4.2.Non-Viral Drug Delivery Systems Key Manufacturers in Asia Pacific
    • 10.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4.Asia Pacific Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.4.5.Asia Pacific Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.4.6.Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.7.India
      • 10.4.7.1.Overview
      • 10.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3.India Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.7.4.India Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.7.5.India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.8.China
      • 10.4.8.1.Overview
      • 10.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3.China Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.8.4.China Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.8.5.China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.9.Japan
      • 10.4.9.1.Overview
      • 10.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3.Japan Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.9.4.Japan Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.9.5.Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.10.South Korea
      • 10.4.10.1.Overview
      • 10.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3.South Korea Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.10.4.South Korea Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.10.5.South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.11.Australia
      • 10.4.11.1.Overview
      • 10.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3.Australia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.11.4.Australia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.11.5.Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.12.Thailand
      • 10.4.12.1.Overview
      • 10.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3.Thailand Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.12.4.Thailand Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.12.5.Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.13.Indonesia
      • 10.4.13.1.Overview
      • 10.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3.Indonesia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.13.4.Indonesia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.13.5.Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.14.Philippines
      • 10.4.14.1.Overview
      • 10.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3.Philippines Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.14.4.Philippines Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.14.5.Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.15.Rest of APAC
      • 10.4.15.1.Overview
      • 10.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3.Rest of APAC Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.15.4.Rest of APAC Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.15.5.Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.5.Latin America
    • 10.5.1.Overview
    • 10.5.2.Non-Viral Drug Delivery Systems Key Manufacturers in Latin America
    • 10.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4.Latin America Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.5.5.Latin America Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.5.6.Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.7.Brazil
      • 10.5.7.1.Overview
      • 10.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3.Brazil Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.7.4.Brazil Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.7.5.Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.8.Mexico
      • 10.5.8.1.Overview
      • 10.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3.Mexico Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.8.4.Mexico Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.8.5.Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.9.Argentina
      • 10.5.9.1.Overview
      • 10.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3.Argentina Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.9.4.Argentina Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.9.5.Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.10.Colombia
      • 10.5.10.1.Overview
      • 10.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3.Colombia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.10.4.Colombia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.10.5.Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.11.Rest of LATAM
      • 10.5.11.1.Overview
      • 10.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3.Rest of LATAM Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.11.4.Rest of LATAM Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.11.5.Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.6.Middle East and Africa
    • 10.6.1.Overview
    • 10.6.2.Non-Viral Drug Delivery Systems Key Manufacturers in Middle East and Africa
    • 10.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4.Middle East and Africa Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.6.5.Middle East and Africa Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.6.6.Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.7.Saudi Arabia
      • 10.6.7.1.Overview
      • 10.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3.Saudi Arabia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.7.4.Saudi Arabia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.7.5.Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.8.United Arab Emirates
      • 10.6.8.1.Overview
      • 10.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3.United Arab Emirates Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.8.4.United Arab Emirates Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.8.5.United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.9.Israel
      • 10.6.9.1.Overview
      • 10.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3.Israel Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.9.4.Israel Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.9.5.Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.10.Turkey
      • 10.6.10.1.Overview
      • 10.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3.Turkey Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.10.4.Turkey Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.10.5.Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.11.Algeria
      • 10.6.11.1.Overview
      • 10.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3.Algeria Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.11.4.Algeria Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.11.5.Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.12.Egypt
      • 10.6.12.1.Overview
      • 10.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3.Egypt Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.12.4.Egypt Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.12.5.Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.13.Rest of MEA
      • 10.6.13.1.Overview
      • 10.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3.Rest of MEA Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.13.4.Rest of MEA Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.13.5.Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

11.Key Vendor Analysis- Non-Viral Drug Delivery Systems Industry

  • 11.1.Competitive Dashboard
  • 11.2.Company Profiles
    • 11.2.1.Arcturus Therapeutics
    • 11.2.2.Bio-Path Holdings
    • 11.2.3.CureVac
    • 11.2.4.Entos Pharmaceuticals
    • 11.2.5.eTheRNA
    • 11.2.6.Matinas BioPharma
    • 11.2.7.MDimune
    • 11.2.8.PCI Biotech

12.360 Degree Analyst View

13.Appendix

  • 13.1.Research Therapeutic Areaology
  • 13.2.References
  • 13.3.Abbreviations
  • 13.4.Disclaimer
  • 13.5.Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Non-Viral Drug Delivery Systems Market: Molecules Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Molecules
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Molecules 2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Biologics Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Biologics
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Biologics 2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Therapeutic AreaSnapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Therapeutic Area2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Region 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)